Breast Cancer Treatment Guidelines

Introduction to Abemaciclib Administration

The American Society of Clinical Oncology and the European Society for Medical Oncology recommend administering abemaciclib orally at a dose of 150 mg twice daily in combination with endocrine therapy for early breast cancer 1, 2

For metastatic breast cancer, the National Comprehensive Cancer Network recommends a dose of 150 mg twice daily in combination with endocrine therapy, and 200 mg twice daily as monotherapy 3
Treatment should be continued until disease progression or unacceptable toxicity, as recommended by the National Comprehensive Cancer Network 3
The standard dosage of abemaciclib is 150 mg taken orally twice daily, which is the established therapeutic dose for both metastatic breast cancer and adjuvant treatment of early breast cancer, according to the American Society of Clinical Oncology 4, 1

Common adverse events include diarrhea (83.5% of patients), neutropenia (45.8% of patients), and fatigue (40.6% of patients), according to the Journal of Clinical Oncology 1
Regular assessment is necessary for adverse events, particularly diarrhea, neutropenia, thromboembolic events (3% of patients), and interstitial lung disease (3% of patients), as reported by the Journal of Clinical Oncology 1
Fatal adverse events occurred in 0.8% of patients taking abemaciclib plus endocrine therapy in clinical trials, highlighting the need for careful management, as reported by the American Society of Clinical Oncology and the Journal of Clinical Oncology 1
Other significant adverse events include thromboembolic events (5.3%) and interstitial lung disease (3.4%), as noted by the American College of Clinical Oncology 1

Abemaciclib has shown significant improvement in invasive disease-free survival when added to endocrine therapy in high-risk early breast cancer patients, with a hazard ratio of 0.70 (95% CI, 0.59 to 0.82), as reported by the Journal of Clinical Oncology 1
Abemaciclib is indicated for hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence, with a dose of 150 mg twice daily, administered with endocrine therapy, as recommended by the American College of Clinical Oncology 4, 1